Variabilidade da protease NS3 do vírus da hepatite C e avaliação das mutações de resistência em pacientes não tratados com inibidores de protease

Pós-graduação em Pesquisa e Desenvolvimento (Biotecnologia Médica) - FMB

Avaliação fitoquímica e microbiológica da espécie Artemisia annua L., submetida a tratamentos de armazenamento e condições de ambiente

Pós-graduação em Agronomia (Energia na Agricultura) - FCA

Efeitos do sevofluorano e do desfluorano sobre variáveis intracranianas e hemodinâmicas em cães

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Índice biespectral, variáveis intracranianas e cardiovasculares em cães anestesiados com diferentes doses de infusão de propofol, associados ou não ao óxido nitroso

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

O coração é um orgão-alvo na pré-eclâmpsia

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.

Hyoscine-N-butylbromide premedication on cardiovascular variables of horses sedated with medetomidine

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Concordância entre o débito cardíaco estimado através das técnicas de termodiluição transpulmonar e de análise de contorno de pulso e a técnica de termodiluição de artéria pulmonar em cães anestesiados com isoflurano

Pós-graduação em Anestesiologia - FMB

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin +/- amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial

Introduction. A large number of patients with chronic hepatitis C have not been cured with interferon-based therapy. Therefore, we evaluated the efficacy of amantadine combined with the standard of care (pegylated interferon plus ribavirin) in patients who had not responded to or had relapsed after 24 weeks of treatment with conventional interferon plus ribavirin. Material and methods. Patients stratified by previous response (i.e., non-response or relapse) were randomized to 48 weeks of open-label treatment with peginterferon alfa-2a (401(D) 180 pg/week plus ribavirin 1,000/1,200 mg/day plus amantadine 200 mg/day (triple therapy), or the standard of care (peginterferon alfa-2a [40KD] plus ribavirin). Results. The primary outcome was sustained virological response (SVR), defined as undetectable hepatitis C virus RNA in serum (< 50 IU/mL) at end of follow-up (week 72). Among patients with a previous non-response, 12/53 (22.6%; 95% confidence interval [CI] 12.3-36.2%) randomized to triple therapy achieved an SVR compared with 16/52 (30.8%; 95% CI 18.7-45.1%) randomized to the standard of care. Among patients with a previous relapse 22/39 (56.4%; 95% CI 39.6-72.2%) randomized to triple therapy achieved an SVR compared with 23/38 (60.5%; 95% CI 43.4-76.0%) randomized to the standard of care. Undetectable HCV RNA (< 50 IU/mL) at week 12 had a high positive predictive value for SVR. A substantial proportion of non-responders and relapsers to conventional interferon plus ribavirin achieve an SVR when re-treated with peginterferon alfa-2a (40KD) plus ribavirin. Conclusion. Amantadine does not enhance SVR rates in previously treated patients with chronic hepatitis C and cannot be recommended in this setting.

Avaliação fitoquímica e microbiológica da espécia Artemisia annua L. submetida a tratamentos de armazenamento e condições de ambiente

The species Artemisia annua L. (Asteraceae) is native to China and has artemisinin as its main active component, substance that is considered a potent antimalarial drug. With the increased interest in natural active principles, studies related to post-harvest and storage of vegetable material become important for better conservation of its phytotherapic properties. Therefore, the present study had as objectivedefine the best storage conditions to preserve and keep the quality of phytotherapic drugs. Leaves of A. annua dried were stored for six months in polyethylene bags wrapped in Kraft paper and packed in four treatments: at ambient condition, refrigerated at 4 ± 2 oC, using normal packing, and using vacuum packing. Samples were taken for microbiological, moisture content, and level of artemisinin analyses before the experiment begun and at 30, 90, 120 and 180 days. The results of microbiological tests showed no significant contamination, as well as the moisture content of the stored (biological) material, which remain between 5% and 10%, keeping within acceptable parameters. The ambient without vacuum treatment (SVA) was the treatment that better maintained the sample stability during 180 days, however, the refrigerated without vacuum (SVR) showed greater efficiency to conserve the content of artemisinin.

Investigação do Ângulo de Fase como preditor da resposta virológica em pacientes portadores de hepatite C

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)